Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.

IF 5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Yumin Wu, Liangzhu Feng
{"title":"Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.","authors":"Yumin Wu,&nbsp;Liangzhu Feng","doi":"10.1080/17425247.2023.2168640","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cancer vaccine represents a promising strategy toward personalized immunotherapy, and its therapeutic potency highly relies on the specificity of tumor antigens. Among these extensively studied tumor antigens, neoantigens, a type of short synthetic peptides derived from random somatic mutations, have been shown to be able to elicit tumor-specific antitumor immune response for tumor suppression. However, challenges remain in the efficient and safe delivery of neoantigens to antigen-presenting cells inside lymph nodes for eliciting potent and sustained antitumor immune responses. The rapid advance of biomaterials including various nanomaterials, injectable hydrogels, and macroscopic scaffolds has been found to hold great promises to facilitate the construction of efficient cancer vaccines attributing to their high loading and controllable release capacities.</p><p><strong>Areas covered: </strong>In this review, we will summarize and discuss the recent advances in the utilization of different types of biomaterials to construct neoantigen-based cancer vaccines, followed by a simple perspective on the future development of such biomaterial-assisted cancer neoantigen vaccination and personalized immunotherapy.</p><p><strong>Expert opinion: </strong>These latest progresses in biomaterial-assisted cancer vaccinations have shown great promises in boosting substantially potentiated tumor-specific antitumor immunity to suppress tumor growth, thus preventing tumor metastasis and recurrence.</p>","PeriodicalId":12229,"journal":{"name":"Expert Opinion on Drug Delivery","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425247.2023.2168640","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Cancer vaccine represents a promising strategy toward personalized immunotherapy, and its therapeutic potency highly relies on the specificity of tumor antigens. Among these extensively studied tumor antigens, neoantigens, a type of short synthetic peptides derived from random somatic mutations, have been shown to be able to elicit tumor-specific antitumor immune response for tumor suppression. However, challenges remain in the efficient and safe delivery of neoantigens to antigen-presenting cells inside lymph nodes for eliciting potent and sustained antitumor immune responses. The rapid advance of biomaterials including various nanomaterials, injectable hydrogels, and macroscopic scaffolds has been found to hold great promises to facilitate the construction of efficient cancer vaccines attributing to their high loading and controllable release capacities.

Areas covered: In this review, we will summarize and discuss the recent advances in the utilization of different types of biomaterials to construct neoantigen-based cancer vaccines, followed by a simple perspective on the future development of such biomaterial-assisted cancer neoantigen vaccination and personalized immunotherapy.

Expert opinion: These latest progresses in biomaterial-assisted cancer vaccinations have shown great promises in boosting substantially potentiated tumor-specific antitumor immunity to suppress tumor growth, thus preventing tumor metastasis and recurrence.

生物材料辅助构建个体化肿瘤免疫治疗新抗原疫苗。
导读:癌症疫苗是一种很有前途的个性化免疫治疗策略,其治疗效果高度依赖于肿瘤抗原的特异性。在这些被广泛研究的肿瘤抗原中,新抗原是一种由随机体细胞突变产生的短合成肽,已被证明能够引发肿瘤特异性抗肿瘤免疫反应,从而抑制肿瘤。然而,如何高效、安全地将新抗原递送到淋巴结内的抗原呈递细胞,以引发有效和持续的抗肿瘤免疫反应,仍是一个挑战。生物材料的快速发展,包括各种纳米材料、可注射水凝胶和宏观支架,由于其高负荷和可控的释放能力,人们发现它们对构建高效的癌症疫苗有很大的希望。综述了近年来利用不同类型的生物材料构建基于新抗原的癌症疫苗的研究进展,并对生物材料辅助癌症新抗原疫苗接种和个性化免疫治疗的未来发展进行了展望。专家意见:这些生物材料辅助癌症疫苗的最新进展显示出极大的希望,可以增强肿瘤特异性抗肿瘤免疫,从而抑制肿瘤生长,从而防止肿瘤转移和复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.10
自引率
3.00%
发文量
104
审稿时长
3 months
期刊介绍: Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信